Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study

Objective This study evaluates the safety/efficacy of sabatolimab plus spartalizumab in patients with melanoma or non-small cell lung cancer (NSCLC).Design, setting and participants This is a phase 1–1b/2, open-label, multinational, multicentre study of patients with advanced/metastatic melanoma or...

Повний опис

Бібліографічні деталі

Автори:	Toshihiko Doi, David Tai, Dong-Wan Kim, F Stephen Hodi, Sofie Wilgenhof, Catherine Sabatos-Peyton, Giuseppe Curigliano, Chia-Chi Lin, Armando Santoro, Alexandros Xyrafas, Nicolas Mach, Sebastian Szpakowski, Shripad Chitnis, Sabine Gutzwiller, Alessandro Pastore
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMJ Publishing Group 2024-08-01
Серія:	BMJ Open
Онлайн доступ:	https://bmjopen.bmj.com/content/14/8/e079132.full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!